[Indications for immunosuppressive treatment in kidney diseases of children].
D000477:Alkylating Agents / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000963:Antimetabolites / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008466:Mechlorethamine / Q000627:therapeutic use; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use
D000477:Alkylating Agents; D000900:Anti-Bacterial Agents; D000963:Antimetabolites; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D002699:Chlorambucil; D003609:Dactinomycin; D008466:Mechlorethamine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate
Wskazania do leczenia immunosupresyjnego w chorobach nerek u dzieci.